
A clear patency benefit of a drug-eluting stent (DES) over a bare metal stent (BMS) for treating peripheral artery disease of the femoropopliteal segment has not been definitively demonstrated. Therefore, the EMINENT study was designed to evaluate the patency of the Eluvia DES, a polymer-coated paclitaxel-eluting stent, compared with BMS for the treatment of femoropopliteal artery lesions. By demonstrating superior 1-year primary patency, the results of the EMINENT randomized study support the benefit of using a polymer-based paclitaxel-eluting stent as a first-line intervention for patients with symptomatic peripheral artery disease attributable to the femoropopliteal disease.
Like
Save
Share